The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ: REPL) surged 17% following the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...

Replimune Group ( REPL, Financials) shares surged 17% to $11.85 as of 10:18 a.m. ET Tuesday after the U.S. Food and Drug ...

The future of skin cancer treatment looks even more promising. Advances in artificial intelligence (AI) are revolutionizing ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated ...

Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.32%, China's Shanghai Composite Index falling 0.05%, ...

Pharmac is also consulting on a joint proposal with Medsafe to increase access to ADHD medicines. The consultation is considering changes to the regulations and funding restrictions stimulant ...

There are seven women who remain on the list of 33 hostages expected to be released from Hamas captivity in the first phase of the hostage deal. Information ...

Trump Asserts a Muscular Vision of Presidential Power as He Takes Over In a flurry of executive actions, President Trump revived disputed claims of broad presidential authority from his first term ...

Kiwis are being encouraged to have their say on proposals to fund six more medicines and change the brand of one medicine ...